Physician profile
Deepika Chona
NPI 1942687066
$5,239.99
in general payments reported to CMS, 2019-2025
23 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.27 · 2022: $665 · 2023: $1,224 · 2024: $1,791 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,494 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.80 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,895.99 | 2021-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $975.21 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $263.43 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $247.24 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $235.32 | 2024-2025 | Vowst |
| Gilead Sciences, INC. | $211.12 | 2022-2025 | |
| Janssen Biotech, INC. | $201.68 | 2022-2025 | Tremfya, Stelara |
| Celgene Corporation | $189.44 | 2022-2024 | Zeposia |
| Pfizer INC. | $176.70 | 2023-2025 | |
| Lilly USA, LLC | $115.99 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $112.79 | 2023-2024 | Linzess |
| Madrigal Pharmaceuticals | $110.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $102.65 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $91.59 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $87.92 | 2022-2023 | Andexxa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.73 | 2022-2024 | Dificid |
| Redhill Biopharma INC. | $45.40 | 2022-2024 | Talicia |
| Pentax of America, INC. | $30.33 | 2024 | Pentax Medical, C2 Cryoballoon Focal Controller, Inspira |
| Alnylam Pharmaceuticals INC. | $26.70 | 2025 | Givlaari |
| Alexion Pharmaceuticals, INC. | $26.50 | 2021 | |
| Novo Nordisk INC | $22.63 | 2025 | Wegovy |
| Shield Therapeutics INC | $14.92 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,142.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Chona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.